Lake Street analyst Frank Takkinen reiterated a Buy rating on Inotiv (NOTV – Research Report) today and set a price target of $10.00. The company’s shares closed last Friday at $3.59.
According to TipRanks, Takkinen is a 4-star analyst with an average return of 8.3% and a 41.18% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as NeuroPace, Apyx Medical, and Inspire Medical Systems.
Currently, the analyst consensus on Inotiv is a Strong Buy with an average price target of $11.75.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $8.28 and a one-year low of $1.61. Currently, Inotiv has an average volume of 242.4K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NOTV in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inotiv (NOTV) Company Description:
Bioanalytical Systems, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
Read More on NOTV:
- NOTV Earnings this Week: How Will it Perform?
- PetVivo announces release of clinical study results on Spryng
- Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024
- Inotiv price target lowered by $9 at Craig-Hallum, here’s why
- Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update
